Exane Derivatives’s Diageo DEO Stock Holding History

Exane Derivatives’s Portfolio DEO Stock Details DEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-70	Closed	-$2.56K	–	591
2017 Q2	$2.56K	Sell	70 -40	-36%	-$4.76K	﹤0.01%	443
2017 Q1	$20.2K	Buy	+110	New	+$12.3K	﹤0.01%	326
2016 Q1	–	Sell	-8	Closed	-$3.84K	–	595
2015 Q4	$3.84K	Hold	8	–	–	﹤0.01%	369
2015 Q3	$9.12K	Buy	+8	New	+$889	﹤0.01%	350

Other funds holding DEO

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Thomaspartners Boston, Massachusetts $13.7B AUM 8.42% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HMP

HS Management Partners New York $286M AUM 2.97% 1-Year Est. Return

Exane Derivatives's DEO Position: Q4 2016 in Review

Exane Derivatives sold out of Diageo (DEO) in Q4 2016, closing a stake of 54 shares — an estimated $6.27K sold.

Exane Derivatives first reported a position in DEO in Q4 2015 and held it in 3 quarters. The position peaked at $52.7K in Q2 2016. 678 funds tracked by Wall St. Rank hold DEO as of Q4 2016.

Exane Derivatives reported no remaining Diageo position as of Q4 2016 after selling out during the quarter.
Exane Derivatives sold 54 Diageo shares in Q4 2016, an estimated $6.27K.
Exane Derivatives first reported a position in Diageo in Q4 2015 and held it in 3 quarters.
Exane Derivatives's Diageo position peaked at $52.7K in Q2 2016.
678 funds tracked by Wall St. Rank held Diageo as of Q4 2016.

Based on Exane Derivatives's 13F filing for Q4 2016, filed 27 Jan 2017.